Address 850 Lincoln Centre Drive, Foster City, CA 94404 Phone number (800) 327-3002 or (650) 638-5800 Fax number (650) 638-5884 Internet address www.appliedbiosystems.com Management Michael Hunkapiller, president Patrick Carroll, senior vice president of worldwide sales and service Robert Jones, vice president of research and development Paul Grossman, vice president of intellectual property Deborah Smeltzer, vice president, knowledge business Year Established 1981 IPO Year 1983
BioWorld Genomics Review | Wednesday, March 12, 2003
Address 1288 Pear Avenue, Mountain View, CA 94043 Phone number (650) 210-1200 Fax number (650) 210-1210 Internet address www.aclara.com Management Joseph Limber, president and CEO Alfred Merriweather, vice president, finance, and CFO Dennis Harris, senior vice president, research and development Stephen Macevicz, vice president, intellectual property Thomas McNaughton, vice president, legal affairs Year Established 1995 (spun off as Soane BioSciences Inc.) IPO Year 2000; NASDAQ
BioWorld Genomics Review | Wednesday, March 12, 2003
Address 1020 Stony Hill Road, Suite 300, Yardley, PA 19067 Phone number (267) 757-7200 Fax number (267) 757-7283 Internet address www.3dp.com Management David U'Prichard, CEO Scott Horvitz, CFO F. Raymond Salemme, president and CSO John Gill, COO Roger Bone, senior vice president for research and development Year Established 1993 IPO Year 2000; NASDAQ:DDDP Employees Approximately 200 Business/Strategy 3-Dimensional Pharmaceuticals Inc. is a drug discovery company that has
BioWorld Genomics Review | Wednesday, March 12, 2003
Without question, the world of science features its fair share of frontiers, and the sequencing of the human genome was among the most recent and significant to be crossed. The field of genomics took a major step forward in the summer of 2000 when the Human Genome Project's working draft was completed by public and private researchers. Instead of following its planned 15-year schedule, researchers were able to shave two years off the timetable. The international effort now aims to fill in most
BioWorld Genomics Review | Wednesday, March 12, 2003
National Editor If proteomics - defined as the study of proteins expressed by a cell, organism, or tissue type in disease or in particular conditions - is (as most agree) the next step after genomics, then haplotype research must be the next step after single nucleotide polymorphism research. In both cases, each sector can help the other, especially in the field of pharmacogenomics, the study of drug responses based on genetic factors. Frost & Sullivan said in late 2002 that the SNP detection
By Randall Osborne | BioWorld Genomics Review | Wednesday, March 12, 2003
National Editor One of the hardy survivors in the genomics shakeout - and something of a case study for those trying to figure out how to make the technology work within a business model - is Myriad Genetics Inc., which couples predictive medicine with drug development. Since 1991, that's been the company's plan. Others in the field found themselves scrambling when the genomics blessing turned to curse and investors began pounding the table for products, but Myriad was ready. President and
By Randall Osborne | BioWorld Genomics Review | Wednesday, March 12, 2003
National Editor In a time when reliable measures of the shifting fortunes of genomics and its subsectors are hard to find, the World Genomics Symposium and Exhibition in Atlantic City in the fall of 2002 proved as good a barometer as any. The mood hardly was bright. Although the event took place in September - a little more than one year after the day that is now referred to simply as "9/11," when terrorist attacks on the U.S. slammed hard into the biotechnology market and all others - its
By Randall Osborne | BioWorld Genomics Review | Wednesday, March 12, 2003
Address 75 Sidney Street, Cambridge, MA 02139 Phone number (617) 679-7000 Fax number (617) 375-7788 Internet address www.millennium.com Management Mark Levin, chairman and CEO Kenneth Bate, CFO Robert Tepper, president, research and development John Douglas, senior vice president and general counsel Linda Pine, senior vice president of human resources Year Established 1993 IPO Year 1996; NASDAQ:MLNM Employees 1,900 Business/Strategy Millennium Pharmaceuticals Inc.'s research
BioWorld Genomics Review | Tuesday, March 11, 2003
Address 1600 Faraday Avenue, P.O. Box 6482, Carlsbad, CA 92008 Phone number (760) 603-7200 Fax number (760) 602-6500 Internet address www.invitrogen.com Management Lyle Turner, president and CEO C. Eric Winzer, CFO John Carrino, vice president of research and development James Glynn, executive vice president Vic Nole, president, cell culture division Year Established 1987 IPO Year 1999; NASDAQ:IVGN Employees 2,500 worldwide Business/Strategy Invitrogen Corp. develops
BioWorld Genomics Review | Tuesday, March 11, 2003
Address 9410 Key West Avenue, Rockville, MD 20850 Phone number (301) 309-8504 Fax number (301) 309-8512 Internet address www.hgsi.com Management William Haseltine, chairman and CEO Steven Mayer, senior vice president and CFO Craig Rosen, executive vice president, research and development David Stump, senior vice president, drug development Year Established 1992 IPO Year 1993; NASDAQ:HGSI Employees 1,010 Business/Strategy The goal of Human Genome Sciences Inc. is to become a
BioWorld Genomics Review | Tuesday, March 11, 2003
Address 45 West Guide Drive, Rockville, MD 20850 Phone number (240) 453-3000 Fax number (240) 453-4000 Internet address www.celera.com Management Kathy Ordo ez, president Ugo DeBlasi, vice president, finance Robert Booth, CSO David Block, senior vice president, Celera, and COO, Celera Therapeutics Michael Venuti, senior vice president, research, and general manager, Celera South San Francisco Year Established 1998 IPO Year 1999; NYSE:CRA (holders of Applera Corp.-Celera Genomics
BioWorld Genomics Review | Tuesday, March 11, 2003
Address 395 Page Mill Road, P.O. Box 10395, Palo Alto, CA 94303 Phone number (650) 752-5000 Fax number (650) 752-5633 Internet address www.agilent.com Management Edward Barnholt, chairman, president and CEO Adrian Dillon, executive vice president and CFO Thomas Saponas, senior vice president and chief technology officer William Sullivan, executive vice president and COO Year Established 1999 (spun out from the Hewlett-Packard Company) IPO Year 1999; NYSE:A Employees
BioWorld Genomics Review | Tuesday, March 11, 2003
Address Affymetrix Inc. 3380 Central Expressway, Santa Clara, CA 95051 Phone number (888) 362-2447 Fax number (408) 731-5441 Internet address www.affymetrix.com Management Stephen Fodor, chairman and CEO Susan Siegel, president Gregory Schiffman, vice president and CFO Trevor Nicholls, chief commercial officer, global operations Robert Ellis, executive vice president, product development and quality Barbara Caulfield, executive vice president and general counsel Year Established
BioWorld Genomics Review | Tuesday, March 11, 2003
National Editor In August 1998, when Perkin-Elmer Corp. and The Institute for Genomic Research put the name Celera Genomics Group on their joint venture to sequence the human genome - deriving it from "celerity," meaning swiftness - the landscape of the sector was altogether different. The government had declared its $3 billion Human Genome Project would have the sequence completed by 2005, and Celera, putting $200 million into its mission, vowed to beat the publicly funded effort. Passion
By Randall Osborne | BioWorld Genomics Review | Tuesday, March 11, 2003
3100 Woodcreek Drive Downers Grove, IL 60515-5400 Phone: 630-271-7000 www.vysis.com John Bishop, president and CEO Wholly owned subsidiary of Abbott Laboratories Overview Incorporated in 1991, Vysis is a genomic disease management company that develops, commercializes and markets clinical products providing information for the evaluation and management of cancer, prenatal disorders and other genetic diseases. Vysis has European operations in Germany, the United Kingdom and France
7 F, No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan and Tainan Science-based Industrial Park, Tainan, Taiwan www.vitagenomics.com Ellson Chen, president and CEO Privately Held Overview Vita Genomics Inc. aims to become a premier genomics-based company focused on improving biological products and understanding diseases prevalent in the Asia Pacific region. The company is in the process of creating an Asia-specific cSNP database as well as a disease-oriented genomic
6H Gill Street Woburn, MA 01801 Phone: 781-937-5550 www.usgenomics.com Eugene Chan, chairman and CEO Privately Held Overview Founded in 1997, U.S. Genomics’ focus is developing technologies to make full use of genomic information. To this end, the company’s technologies employ the direct and linear reading of large sections of genomes. U.S. Genomics’s technology platform, the GeneEngine, has two components: nanotechnology systems for positioning DNA so that it can be read linearly
500 Beacon Parkway West Birmingham, AL 35209 Phone: 205-943 8478 www.tranzyme.com Vipin Garg, CEO Privately Held Overview Tranzyme’s technology has the capability to study gene function and protein expression in clinically relevant biological systems. This capability helps in gene function analysis and for building biological assays for drug discovery. The company specializes in bringing biology to chemistry-driven companies. Founded in 1998, Tranzyme has developed proprietary
Warthestrasse 21 D-14513 Teltow/Berlin Germany Phone: +49 3328 3508 61 www.wita-proteomics.com Andreas Kpke, CEO Privately Held Overview WITA Proteomics AG, spun out of WITA GmbH in March 2001, is a proteomics company identifying disease-related proteins for the diagnostic, drug development and predictive toxicology markets using its High Performance Proteomics technology. The High Performance Proteomics platform provides ultra-high-resolution analytical and preparative 2-D gel
Address 850 Lincoln Centre Drive, Foster City, CA 94404 Phone number (800) 327-3002 or (650) 638-5800 Fax number (650) 638-5884 Internet address www.appliedbiosystems.com Management Michael Hunkapiller, president Patrick Carroll, senior vice president of worldwide sales and service Robert Jones, vice president of research and development Paul Grossman, vice president of intellectual property Deborah Smeltzer, vice president, knowledge business Year Established 1981 IPO Year 1983